Savara (NASDAQ:SVRA) Shares Up 6.8% – Here’s Why

Savara Inc. (NASDAQ:SVRA) shares rose 6.8% during mid-day trading on Thursday . The stock traded as high as $5.74 and last traded at $5.7150. Approximately 553,116 shares traded hands during mid-day trading, a decline of 61% from the average daily volume of 1,422,530 shares. The stock had previously closed at $5.35.

Wall Street Analyst Weigh In

Several analysts have recently commented on SVRA shares. Oppenheimer set a $10.00 target price on Savara in a report on Tuesday, December 23rd. Citigroup reaffirmed an “outperform” rating on shares of Savara in a report on Thursday, October 23rd. UBS Group set a $10.00 price objective on shares of Savara in a report on Tuesday, December 23rd. Wall Street Zen upgraded shares of Savara from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Savara in a research note on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $9.13.

Savara Price Performance

The company has a fifty day simple moving average of $5.99 and a two-hundred day simple moving average of $4.52. The company has a current ratio of 7.65, a quick ratio of 7.65 and a debt-to-equity ratio of 0.32. The stock has a market capitalization of $1.19 billion, a P/E ratio of -11.00 and a beta of 0.34.

Savara (NASDAQ:SVRA) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.01). Sell-side analysts expect that Savara Inc. will post -0.45 EPS for the current fiscal year.

Hedge Funds Weigh In On Savara

Several hedge funds have recently added to or reduced their stakes in the stock. Prudential Financial Inc. bought a new stake in shares of Savara in the 2nd quarter valued at about $30,000. BNP Paribas Financial Markets increased its stake in Savara by 52.3% in the second quarter. BNP Paribas Financial Markets now owns 13,473 shares of the company’s stock valued at $31,000 after purchasing an additional 4,626 shares in the last quarter. May Hill Capital LLC bought a new position in shares of Savara during the second quarter worth $32,000. Brevan Howard Capital Management LP acquired a new position in shares of Savara in the 2nd quarter valued at $33,000. Finally, Russell Investments Group Ltd. increased its position in shares of Savara by 930.5% in the 3rd quarter. Russell Investments Group Ltd. now owns 10,480 shares of the company’s stock valued at $37,000 after buying an additional 9,463 shares in the last quarter. Institutional investors and hedge funds own 87.93% of the company’s stock.

About Savara

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.